Scientists probe IL-6's role in amino acid control
NCT ID NCT06721910
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This completed study in 26 healthy volunteers tested whether blocking interleukin-6 (IL-6) changes how glucagon lowers amino acid levels in the blood. Participants received either a placebo or tocilizumab, a drug that blocks IL-6, followed by hormone infusions to mimic fasting and fed states. Researchers measured amino acid levels and other markers to understand IL-6's role in protein balance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital Basel
Basel, 4031, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tocilizumab (a drug that blocks interleukin-6 receptor)
What this could lead to
If successful, this could help understand how IL-6 contributes to amino acid imbalances in conditions like diabetes or liver disease.
What could go wrong
This is a small, early-stage proof-of-concept study in healthy people, not patients. Results may not apply to real-world diseases.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.